|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #redirect [[Simvastatin#Adult Indications and Dosage]] |
| {{Simvastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to [hypercholesterolemia]]. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and [[cholesterol]] and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, ZOCOR<sup>1</sup> can be started simultaneously with diet.
| |
| | |
| <sup>1</sup>
| |
| Registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
| |
| Copyright © 1999-2012 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
| |
| All rights reserved
| |
| | |
| ===Reductions in Risk of CHD Mortality and Cardiovascular Events===
| |
| | |
| In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, ZOCOR is indicated to:
| |
| | |
| Reduce the risk of total mortality by reducing CHD deaths.
| |
| Reduce the risk of non-fatal [[myocardial infarction]] and stroke.
| |
| Reduce the need for coronary and non-coronary revascularization procedures.
| |
| | |
| ===Hyperlipidemia===
| |
| | |
| ZOCOR is indicated to:
| |
| | |
| Reduce elevated total [[cholesterol]] (total-C), low-density lipoprotein [[cholesterol]] (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein [[cholesterol]] (HDL-C) in patients with primary [[hyperlipidemia]] (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed [[dyslipidemia]] (Fredrickson type IIb).
| |
| Reduce elevated TG in patients with [[hypertriglyceridemia ]](Fredrickson type lV [[hyperlipidemia]]).
| |
| Reduce elevated TG and VLDL-C in patients with primary [[dysbetalipoproteinemia]] (Fredrickson type III hyperlipidemia).
| |
| Reduce total-C and LDL-C in patients with homozygous familial [hypercholesterolemia]] (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.
| |
| | |
| ===Adolescent Patients with Heterozygous Familial hypercholesterolemia (HeFH)===
| |
| | |
| ZOCOR is indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present:
| |
| | |
| LDL [[cholesterol]] remains ≥190 mg/dL; or
| |
| LDL [[cholesterol]] remains ≥160 mg/dL and
| |
| | |
| There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient.
| |
| The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C <130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined.
| |
| | |
| ===Limitations of Use===
| |
| | |
| ZOCOR has not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ZOCOR (SIMVASTATIN) TABLET, FILM COATED [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fdbfe194-b845-42c5-bb87-a48118bc72e7 | publisher = | date = | accessdate = 18 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{Statins}}
| |
| {{Merck&Co}}
| |
|
| |
|
| [[Category:Alcohols]] | | [[Category:Alcohols]] |